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OBJECTIVE: To characterize thyroid disturbances induced by interferon-alpha and ribavirin therapy in patients with
chronic hepatitis C.
INTRODUCTION: Interferon-alpha is used to treat chronic hepatitis C infections. This compound commonly induces
both autoimmune and non-autoimmune thyroiditis.
METHODS: We prospectively selected 26 patients with chronic hepatitis C infections. Clinical examinations,
hormonal evaluations, and color-flow Doppler ultrasonography of the thyroid were performed before and during
antiviral therapy.
RESULTS: Of the patients in our study, 54% had no thyroid disorders associated with the interferon-alpha therapy but
showed reduced levels of total T3 along with a decrease in serum alanine aminotransferase. Total T4 levels were also
reduced at 3 and12 months, but free T4 andthyroid stimulating hormone (TSH) levels remained stable. A totalof 19%
of the subjects had autoimmune interferon-induced thyroiditis, which is characterized by an emerge of antithyroid
antibodiesoroverthypothyroidism.Additionally,16%hadnon-autoimmunethyroiditis,whichpresentsasdestructive
thyroiditis or subclinical hypothyroidism, and 11% remained in a state of euthyroidism despite the prior existence of
antithyroidal antibodies. Thyrotoxicosis with destructive thyroiditis was diagnosed within three months of therapy,
and ultrasonography of these patients revealed thyroid shrinkage and discordant change in the vascular patterns.
DISCUSSION: Decreases in the total T3 and total T4 levels may be related to improvements in the hepatocellular
lesions or inflammatory changes similar to those associated with nonthyroidal illnesses. The immune mechanisms
and direct effects of interferon-alpha can be associated with thyroiditis.
CONCLUSION: Interferon-alpha and ribavirin induce autoimmune and non-autoimmune thyroiditis and hormonal
changes (such as decreased total T3 and total T4 levels), which occur despite stable free T4 and TSH levels. A thyroid
hormonal evaluation, including the analysis of the free T4, TSH, and antithyroid antibody levels, should be
mandatory before therapy, and an early re-evaluation within three months of treatment is necessary as an
appropriate follow-up.
KEYWORDS: Thyroid hormones; Hepatitis C; Interferon-induced thyroiditis; Destructive thyroiditis; Thyroid
ultrasonography.
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INTRODUCTION
Hepatitis C is a disease that is disseminated worldwide,
and chronic infections affect up to 80% of the infected
subjects.
1 Consequently, interferon-alpha (IFNa) therapy
has frequently been used. IFNa is one of a group of
cytokines with antiviral, antiproliferative, and immunomo-
dulatory properties. In cases of hepatitis C, the presence of
moderate to severe necroinflammatory activity and/or
moderate to severe fibrosis (as assessed by a liver biopsy)
represent formal indications of IFNa use. The drug is
available in both conventional and pegylated forms and is
frequently used in association with ribavirin, another
antiviral drug.
2,3 The treatment is continuous and lasts
from 6 to 12 months, and retreatment can be necessary.
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1757IFNa has several adverse effects, ranging from influenza-
like symptoms to severe hematologic abnormalities and
pulmonary complications.
4 These adverse effects provoke
dose reduction in up to 40% of cases and treatment
withdrawal in up to 14% of cases.
5
IFNa can commonly induce thyroiditis, which is classified
as either autoimmune or non-autoimmune interferon-
induced thyroiditis (IIT).
6 Autoimmune IIT manifests as
Hashimoto’s thyroiditis, which is defined by an emerge of
or worse in antithyroid antibody levels with or without
hypothyroidism. In rare cases, autoimmune IIT also mani-
fests as Graves’ disease, which is defined by antithyroid
antibodies with hyperthyroidism. Non-autoimmune IIT
presents as destructive thyroiditis and hypothyroidism.
6
Hashimoto’s thyroiditis is diagnosed in up to 40% of
patients, and hypothyroidism can be triggered by IFNa.
7
Hypothyroidism frequently escapes diagnosis due to the
overlap of its symptoms with those induced by IFNa itself,
such as fatigue, somnolence and depression.
Rarely, IFNa induces Graves’ disease, the diagnosis of
which is based on hyperthyroidism with goiter and the
presence of thyroid stimulating hormone receptor antibo-
dies.
7 Its treatment demands precaution due to the hepato-
toxic and hematologic side effects of antithyroid drugs.
Destructive thyroiditis represents a form of non-auto-
immune IIT characterized by self-limited thyrotoxicosis
with a triphasic evolution similar to that of subacute
thyroiditis. In the first phase, the patient shows thyrotox-
icosis, low radioiodine uptake and the absence of antithyr-
oid antibodies. Hypothyroidism follows euthyroidism
within a few weeks to months. Hypothyroidism can persist,
especially in the presence of antithyroid antibodies.
Destructive thyroiditis may recur upon re-treatment, and
it is not necessary to discontinue IFNa use.
6
Our study prospectively characterized the manifestations
of thyroid disturbances induced by IFNa and ribavirin
therapy in chronically HCV-infected subjects.
MATERIALS AND METHODS
Patients
Out of the 112 subjects diagnosed with chronic hepatitis
C and receiving follow-up at the Hospital das Clı ´nicas da
F a c u l d a d ed eM e d i c i n ad aU n i v e r s i d a d ed eS a ˜oP a u l obetween
January 2007 and July 2009, 26 patients who were
beginning IFNa and ribavirin therapy were prospectively
selected. None of the patients had previously been treated
with interferon. The diagnosis of chronic HCV infection
was based on a positive anti-HCV serology and the
presence of viral nucleic acid, as evaluated by polymerase
chain reaction (PCR) using the commercial Amplicor HCV
test (Roche Diagnostics Systems). The type and duration of
the IFNa therapy was based on the viral genotype. Non-
cirrhotic genotypes 2 and 3 received non-pegylated IFNa
for 24 weeks. Cirrhotic genotypes 2 and 3, genotype 1 and
HCV with human immunodeficiency virus (HIV) co-
infection (independent of the HCV genotype) received
pegylated IFNa for 48 weeks, provided that the HCV RNA
became undetectable or that the number of viral copies
decreased at least 2 logs (100-fold) within 12 weeks. Any
patients with HBV infections, those who were pregnant,
and those who were using amiodarone or lithium were
excluded.
The study was approved by the institutional research
ethics committee, and all of the subjects gave their informed
written consent to participate.
Methods
The patients underwent clinical and hormonal evalua-
tions before treatment and every 12 weeks during treatment.
Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were measured using conventional
methods. HCV genotyping was performed using a reverse
hybridization assay, the Line Probe Assay (INNO-LiPA HCV/
VERSANTTM HCV Genotype Assay, Bayer Corporation,
Tarrytown, NY, USA).
Total T3 (TT3), total T4 (TT4), free T4 (FT4), TSH and
thyroglobulin (Tg) levels were measured using commercial
fluoroimmunoassay kits (AutoDELFIAH,U p s a l a ,T u r k u ,
Finland). Serum anti-thyroglobulin (anti-Tg) and anti-thyro-
peroxidase (anti-TPO) antibodies were measured using
commercial indirect fluoroimmunoassay kits (AutoDELFIAH,
Upsala, Turku, Finland). Thyroid-stimulating hormone recep-
tor antibody (TRAb) levels were evaluated by an immunor-
adiometric assay (RSR, Cardiff, Wales, UK).
Hashimoto’s thyroiditis was defined by increased levels
of anti-Tg or anti-TPO antibodies (.35 mUI/L). Subclinical
hypothyroidism was diagnosed when TSH levels were
increased (.4.5 mUI/L) and when FT4 levels were within
the normal range (0.7 – 1.5 ng/dL), whereas overt
hypothyroidism was diagnosed based on increased TSH
levels associated with decreased FT4 levels. Thyrotoxicosis
was characterized by increased FT4 levels and depressed
TSH levels (,0.03 mUI/L). Destructive thyroiditis was
diagnosed by the presence of thyrotoxicosis in the absence
of TRAbs, followed by subclinical or overt hypothyroidism
(either transitory or permanent).
Color-flow Doppler thyroid ultrasonography (CDUS) was
performed by a single investigator (7.5–12 MHz, Philips
HDI 5000 device; Philips Medical Systems, Bothell, WA,
USA) before therapy and after 12 months of therapy. The
thyroid parenchyma and echogenicity, the presence of
nodules, the glandular volume and vascularization were
evaluated. Vascularization was classified according to
Bogazzi et al., as follows: pattern 0, the absence of
intraparenchymal vascularity or minimal spots; pattern I,
the presence of parenchymal blood flow with a patchy and
uneven distribution; pattern II, a mild increase in color-flow
Doppler signal with patchy distribution; pattern III, a
marked increase in color-flow Doppler signal with diffuse
homogeneous distribution.
8
Statistical analysis
The data were processed using SPSS 13.0 software. Two-
tailed p-values were calculated, and p-values of ,0.05 were
considered to be statistically significant.
The categorical variables are presented as absolute and
relative frequencies (percentages). Any differences were
evaluated by Pearson’s x
2 test and Fisher’s exact test, where
appropriate. The continuous variables are presented as the
means ¡ standard deviations. Kolmogorov-Smirnov or
Shapiro-Wilk statistics were used to test for any deviations
from normality. Any differences among the studied
subgroups were determined using Student’s t-test and
one-way ANOVA for the normally distributed data, and
the Mann-Whitney U, Wilcoxon, and Kruskal-Wallis tests
were used for the non-normally distributed data.
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Clinical features
A total of 26 patients, including 15 female patients, were
treated with IFNa and ribavirin. The mean patient age was
43.1¡11.8 years. Of the subjects, 85% had normal thyroid
function and no antithyroid antibodies before the onset of
treatment. Four patients (15%) were diagnosed with
Hashimoto’s thyroiditis with euthyroidism.
Throughout the duration of the IFNa treatment, 14
patients maintained normal thyroid function. IFNa induced
thyroiditis in 35% of the cases. Autoimmune thyroiditis,
which is characterized as an emerge of antithyroidal
antibodies and overt autoimmune hypothyroidism, was
detected in 19% of the cases (two patients). Destructive
thyroiditis occurred in 8% of the patients, and 8% developed
non-autoimmune subclinical hypothyroidism. IIT appeared
after 6.2¡3.3 months of therapy. However, all of the cases of
destructive thyroiditis involved asymptomatic thyrotoxico-
sis, with hormonal diagnosis occurring as early as three
months into the treatment. Finally, 11% of the patients
remained in a state of euthyroidism after hepatitis C therapy
despite the prior presence of antithyroidal antibodies.
Patients with normal thyroid function during IFNa
treatment
In the 14 patients (eight males) with normal thyroid
function before and during the IFNa treatment, a significant
decrease in TT3 levels (p=0.038) was observed after 12
months of therapy, along with a significant reduction in TT4
levels after 3 and 12 months (p=0.039 and p=0.008,
respectively), despite TT3 and TT4 levels falling within the
normal range. Interestingly, the FT4 and TSH levels
remained stable. A decrease in ALT levels (p=0.055),
suggestive of the precocious regression of hepatocellular
lesions, was also noted, although the AST levels presented
no significant decrease (Figure 1).
Patients with interferon-induced thyroiditis
The clinical, hormonal and CDUS characteristics of the
subjects with autoimmune and non-autoimmune IIT were
compared to those of patients with no therapy-related
thyroid disorders (Table 1).
All of the patients who were diagnosed with autoimmune
IIT were female, which represented a significantly higher
number of females (p=0.045) compared to subjects with no
therapy-related thyroid disorders. The pre-treatment levels
of TT3 (141¡18 ng/dL, p=0.018) and TT4 (8.8¡0.7 mg/dL,
p=0.005) were significantly lower, and the TSH levels
tended to be higher (3.1¡1.2 mUI/L, p=0.079) in the
patients with non-autoimmune IIT compared to the patients
with no thyroid disorders (TT3, 184¡36 ng/L; TT4,
11.9¡2.0 mg/dL; TSH, 1.8¡0.7 mUI/L). No differences in
age, race, HIV co-infections, the HCV genotype, the type of
IFNa used (pegylated or non-pegylated), the length of the
therapy and the CDUS features were observed between the
IIT patients and the subjects with no thyroid-related
disorders.
Two subjects developed autoimmune hypothyroidism
during the IFNa treatment. One had prior anti-Tg and anti-
TPO antibodies, and the other had developed both
antibodies at the onset of the hormonal disturbance. No
specific symptoms were reported, even with TSH levels
as high as 123 mU/L and 128 mU/L, respectively.
Levothyroxine replacement therapy was necessary and
was maintained through the final evaluation. The thyroid
disturbances in the cases of autoimmune IIT were unre-
solved during follow-up.
The hormonal dysfunction in both of the cases of non-
autoimmune subclinical hypothyroidism regressed during
or after IFNa withdrawal. One of the cases presented an
asymptomatic TSH increase (5.8 mU/L) within five months
of the IFNa therapy, with subsequent normalization despite
the maintenance of the antiviral therapy. The other case
showed an asymptomatic TSH increase (6.2 mU/L) after ten
months of therapy, and hormonal normalization occurred
six months after IFNa withdrawal.
Two patients had destructive IFNa-induced thyroiditis
IFNa (Figure 2). The first case presented as asymptomatic
thyrotoxicosis within three months of therapy (Figure 2A).
The thyroglobulin levels rose from 27.7 ng/dL to 106 ng/dL.
The tests for the anti-Tg and anti-TPO antibodies and TRAb
remained negative. The initial CDUS revealed heterogeneous
isoechoic parenchyma and increased vascularization (pattern
III), and the glandular volume was 8.4 g. One month after the
diagnosis of thyrotoxicosis, a new examination revealed a
decrease in thyroid vascularization (pattern II) and concomi-
tant glandular shrinkage (42%). Such modifications persisted
during CDUS performed 8.5 months after the end of the
therapy. The second case had a similar evolution (Figure 2B).
The diagnosis of asymptomatic thyrotoxicosis was made
within 3.4 months of the onset of therapy. The thyroglobulin
levels rose from 10.5 ng/dL to 147 ng/dL. Although negative
for TRAb, anti-Tg and anti-TPO antibodies were detected at
low levels (41 UI/L and 66 UI/L, respectively). The initial
CDUS revealed a heterogeneous isoechoic parenchyma and
mildly increased vascularization (pattern II), and the gland-
ular volume was 18 g. Three months after the diagnosis of
thyrotoxicosis, another examination revealed a hypoechoic
parenchyma with increased vascularization (pattern III) and a
14.4% decrease in thyroid volume, which persisted according
to CDUS performed two months after the end of therapy.
DISCUSSION
We performed a careful prospective study of 26 HCV-
infected patients during IFNa and ribavirin treatment, and
only 54% of these patients maintained normal thyroid
function, which should alert the clinician to these important
potential side effects.
Previous data identified a decrease in FT4 levels within
reference values concomitant to a slight reduction in free T3
levels without TSH or thyroglobulin changes during six
months of conventional IFNa therapy.
9 We observed
decreases in both TT3 and TT4 levels within 12 months of
therapy with conventional and pegylated IFNa in associa-
tion with ribavirin.
As FT4 and TSH remained stable, we could not attribute
such hormonal changes to an IFNa-induced organification
defect.
10 The decreases in TT3 and TT4 levels may be related
to interleukin-6 (IL-6). Previous studies have reported an
increase in IL-6 serum levels with conventional and
pegylated IFNa treatments.
11,12 IL-6 reduces thyroperoxidase
mRNAlevelsandTSH-stimulatedthyroidhormonesecretion
separately from decreasing thyroid hormone binding pro-
teins.
13 Therefore, IL-6 reduces TT3 without changes in FT4
or TSH levels. Corssmit et al. reported the acute effects of
IFNa in healthy volunteers.
14 They observed significant
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1759decreases in TT3 and TSH levels along with an increase in
reverse T3 levels without any change in TT4 or FT4 levels.
They attributed the hormonal changes to increases in IL-6
levels and interferon-induced cortisol release. Finally, the
decrease in TT3 and TT4 levels during treatment may be
related to the improvement of the hepatocellular lesions, as
indicated by the reduction in ALT levels. Unfortunately, we
didnotevaluate thyroxine-bindingglobulin (TBG)toconfirm
Figure 1 - Hormonal, thyroglobulin, and aminotransferases changes during the 12-month follow-up of 14 HCV-infected patients with
normal thyroid function during IFNa and ribavirin treatment. Differences were assessed using Kruskal-Wallis tests. * p=0.039 compared
to the initial levels.
# p=0.008 compared to the initial levels. Reference values: TT3, 40 to 180 ng/dL; TT4, 4.5 to 12 mg/dL; FT4, 0.7 to
1.5 ng/dL; TSH, 0.4 to 4.5 mUI/L; Tg,55 ng/dL (by fluoroimmunoassay); AST,37 or ,31 UI/L and ALT,41 or ,31 UI/L for males or
females, respectively.
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1760Table 1 - The characteristics of the subjects with autoimmune and non-autoimmune interferon-induced thyroiditis and
the subjects with no thyroid disorders during interferon-alpha and ribavirin therapy.
No thyroid disorder
(n=14)
Autoimmune IIT
(n=5)
Non-autoimmune IIT
(n=4)
Time to diagnosis (mo) - 6.7¡3.5 9.9¡2.2
Age (years) 44.9¡12.7 35.6¡10.3 48.5¡5.7
Sex (male/female)
a 8/6 0/5 2/2
HIV 2 1 1
HCV genotype
1
2
3
8
0
6
4
0
1
2
1
1
IFNa
Conventional
Pegylated
5
9
0
5
1
3
Duration of therapy (weeks) 33.6¡14.2 39.6¡9.8 42.0¡12.0
Before IFNa:
TT3 (ng/dL)
b
TT4 (mg/dL)
c
FT4 (ng/dL)
TSH (mUI/L)
d
184.7¡35.8
11.9¡2.0
0.9¡0.1
1.8¡0.7
191.8¡27.7
13.2¡2.5
0.9¡0.1
1,8¡1.4
141.8¡17.7
8.8¡0.7
0.8¡0.1
3.1¡1.2
CDUS*:
Heterogeneity (%)
Hypoechogenicity (%)
Glandular volume (g)
Nodules (%)
Vascularization (%)
I
II
III
11 (91.7)
2 (16.7)
12.6¡6.8
5 (41.7)
3 (25.0)
2 (16.7)
7 (58.3)
5 (100)
1 (20.0)
9.3¡2.8
1 (20.0)
0
1 (25.0)
3 (75.0)
3 (75.0)
0 (0)
10.6¡5.1
1 (25.0)
0
1 (33.3)
2 (66.7)
Final CDUS*
Heterogeneity (%)
Hypoechogenicity (%)
Glandular volume (g)
Nodules (%)
Vascularization (%)
I
II
III
9 (81.8)
2 (18.2)
12.7¡5.7
4 (36.4)
1 (11.1)
6 (66.7)
2 (22.2)
2 (100)
1 (50,0)
12.3¡0.7
0 (0)
0 (0)
1 (50.0)
1 (50.0)
4 (100)
2 (50.0)
9.8¡4.9
2 (50.0)
0 (0)
1 (25.0)
3 (75.0)
Reference values: TT3, 40 to 180 ng/dL; TT4, 4.5 to 12 mg/dL; FT4, 0.7 to 1.5 ng/dL; TSH, 0.4 to 4.5 mUI/L (as determined by a fluoroimmunoassay).
n, the number of patients; IIT, interferon-induced thyroiditis; IFNa, interferon-alpha; CDUS, thyroid color-flow Doppler ultrasound.
*the frequency based on the number of patients, with the CDUS results showing the indicated parameter.
ap=0.045 when comparing the groups with no thyroid disorder and autoimmune IIT.
bp=0.018 when comparing the groups with no thyroid disorder and non-autoimmune IIT.
cp=0.005 when comparing the groups with no thyroid disorder and non-autoimmune IIT.
dp=0.079 when comparing the groups with no thyroid disorder and non-autoimmune IIT.
Figure 2 - TSH and FT4 changes during the follow-up of 2 HCV-infected patients with destructive thyroiditis induced by IFNa and
ribavirin. Reference values: FT4, 0.7 to 1.5 ng/dL; TSH, 0.4 to 4.5 mUI/L (as determined by a fluoroimmunoassay).
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1761this hypothesis. Previous studies have suggested that TT3
and TT4 levels increase in cases of chronic liver disease in
proportion to the severity of the liver dysfunction (due to
high TBG levels).
15,16
We confirmed the existence of two main forms of IIT
(autoimmune and non-autoimmune). The mechanisms
involved in autoimmune thyroiditis associated with IFNa
have not yet been clarified. IFNa and its receptor activate
the JAK-STAT pathway, activating the expression of genes
encoding cytokines and adhesion molecules. IFNa also
increases the expression of MHC class I antigens, activates
cytotoxic T cells, and induces the T helper 1-mediated
immune response.
6 The mean time to the diagnosis of IFNa-
induced autoimmune thyroid disturbance was six months,
which suggests that longer exposure is required to stimulate
immune mechanisms.
The direct effects of IFNa on the thyroid may be
responsible for non-autoimmune thyroiditis.
6 It is possible
that HCV itself promotes a local immune response in
thyrocytes. In addition, IFNa directly induces thyrocyte
death and inhibits TSH-induced gene expression and
protein production of Tg, TPO and the sodium iodine
symporter,
17,18 which promote follicular destruction and
hypothyroidism. We found a significant increase in thyr-
oglobulin levels within three months of the onset of therapy
in the cases of destructive thyroiditis, indicating the direct,
acute and destructive effects of IFNa on follicular cells.
Onelimitationof thisstudyisthesmall number ofpatients,
especially those who developed IIT. Nevertheless, we were
ableto identify an association between the female gender and
autoimmune IIT, as previously reported in larger popula-
tions.
19,20 Our data support the conclusion that the develop-
ment of IIT is not related to the type of IFNa (i.e.,
conventional vs. pegylated).
21 We are the first to describe
an association between reduced pre-treatment levels of TT3
and TT4 and slightly increased TSH levels as predictors of
non-autoimmune IIT. We speculate that a smaller thyroid
hormone reserve facilitated the hormonal disturbance after a
direct cellular lesion caused by IFNa.
The higher frequency (8%) of destructive thyroiditis
(compared to previous data)
7,22 is remarkable. This dis-
crepancy may have occurred because of the early hormonal
evaluation that we performed (at three months). CDUS
would help to differentiate thyrotoxicosis caused by either
destructive thyroiditis or auto-immune thyroiditis (Graves’
disease). Unfortunately, Graves’ disease was not diagnosed
during the IFNa therapy. Our patients with destructive
thyroiditis had either mild (pattern II) or marked (pattern
III) increases in vascularization. In contrast to amiodarone-
induced thyroiditis, we expected that destructive thyroiditis
would lead to CDUS patterns of less than II, and
autoimmune thyroiditis would lead to pattern III.
8
Possible explanations for these findings are the use of
delayed CDUS exams for diagnosis and the concomitant
autoimmune mechanisms that were induced, which were
represented by dramatic increases in anti-Tg and anti-TPO
antibody levels (case 2). Both of the patients developed
rapid thyroid volume shrinkage, which is compatible with
destructive lesions. Additional CDUS exams are necessary
to define the role of ultrasound in differentiating IFNa-
induced thyrotoxicosis.
In summary, treating HCV infections with IFNa and
ribavirin induces autoimmune and non-autoimmune thyr-
oiditis and hormonal changes, which are represented by
decreases in TT3 and TT4 levels despite stable levels of FT4
and TSH. Consequently, a thyroid hormonal evaluation,
including measurements of FT4, TSH, and antithyroid
antibody levels, should be mandatory before therapy. As
thyroid disturbances were detected within three months of
treatment, we suggest an early hormonal re-evaluation
during IFNa treatment. Thus, thyroid disturbances will not
remain undiagnosed.
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